Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by investment analysts at Stifel Nicolaus in a note issued to investors on Wednesday. They currently have a $190.00 price target on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ target price points to a potential upside of 30.26% from the company’s current price.

Other equities analysts have also issued research reports about the company. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $177.00 price target (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, August 10th. BidaskClub lowered Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. Finally, Vetr raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price target on the stock in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $180.96.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.08% during trading on Wednesday, hitting $145.74. 322,737 shares of the stock traded hands. The company has a market cap of $8.75 billion, a P/E ratio of 22.45 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The firm has a 50-day moving average price of $152.07 and a 200 day moving average price of $148.41.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. The firm had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.67 earnings per share. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Stifel Nicolaus Reaffirms Buy Rating for Jazz Pharmaceuticals PLC (JAZZ)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/30/stifel-nicolaus-reaffirms-buy-rating-for-jazz-pharmaceuticals-plc-jazz.html.

In other Jazz Pharmaceuticals PLC news, Director Rick E. Winningham sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $150.00, for a total transaction of $750,000.00. Following the sale, the director now owns 10,391 shares in the company, valued at $1,558,650. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick G. Enright sold 351 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $148.40, for a total value of $52,088.40. Following the sale, the director now owns 1,717 shares in the company, valued at approximately $254,802.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,917 shares of company stock worth $1,973,227. Insiders own 4.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after buying an additional 3,116,652 shares during the period. Janus Henderson Group PLC raised its position in shares of Jazz Pharmaceuticals PLC by 11,990.7% in the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock worth $135,894,000 after buying an additional 866,691 shares during the period. FMR LLC raised its position in shares of Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock worth $1,289,159,000 after buying an additional 849,348 shares during the period. Janus Capital Management LLC raised its position in shares of Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock worth $213,367,000 after buying an additional 468,940 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of Jazz Pharmaceuticals PLC by 178.2% in the first quarter. TIAA CREF Investment Management LLC now owns 663,548 shares of the specialty pharmaceutical company’s stock worth $96,301,000 after buying an additional 425,042 shares during the period. 88.24% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.